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A B S T R A C T
Background: Historically, patients with prior coronary artery bypass graft (CABG) surgery undergoing 
primary percutaneous coronary intervention (PCI) have a worse prognosis than patients without prior 
CABG. However, more contemporary analyses have contested these findings. This study’s aim was to 
evaluate the 30-day clinical outcomes in patients with and without prior CABG submitted to primary PCI. 
Methods: Prospective cohort study, extracted from the database of Instituto de Cardiologia do Rio Grande 
do Sul, containing 1,854 patients undergoing primary PCI.
Results: Patients with prior CABG (3.8%) showed, in general, a more severe clinical profile. The time of 
symptom onset until arrival at the hospital was shorter in this group (2.50 hours [1.46 to 3.66] vs. 3.99 
hours [1.99 to 6.50]; p < 0.001), while the door-to-balloon time was similar (1.33 hour [0.85 to 2.07] vs. 
1.16 hour [0.88 to 1.58]; p = 0.12). Femoral access was more often used in the group with prior CABG 
(91.5% vs. 62.5%; p < 0.001). Manual thrombus aspiration was less often performed in this group (16.9% 
vs. 31.1%; p = 0.007), but there was no difference regarding the use of glycoprotein IIb/IIIa inhibitors 
(28.2% vs. 32.4%, p = 0.28). Angiographic success was lower in the group with prior CABG (80.3% vs. 93.3%; 
p = 0.009). At 30 days, patients with prior CABG had similar rates of major adverse cardiac events (14.1% 
vs. 11.2%; p = 0.28), and mortality, although numerically higher, was not statistically significant (13.2% 
vs. 7.0%, p = 0.07). 
Conclusions: In this contemporary analysis, patients with prior CABG undergoing primary PCI had a 
more severe clinical profile and lower angiographic success, but showed no differences regarding 30-day 
clinical outcomes.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Impacto da cirurgia de revascularização miocárdica prévia em desfechos clínicos 
de pacientes submetidos à intervenção coronária percutânea primária
R E S U M O
Introdução: Historicamente, pacientes com cirurgia de revascularização do miocárdio (CRM) prévia 
submetidos à intervenção coronária percutânea (ICP) primária têm pior prognóstico que pacientes sem 
CRM prévia. No entanto, análises mais contemporâneas contestam esses achados. Nosso objetivo foi avaliar 
os desfechos clínicos de 30 dias em pacientes com e sem CRM prévia submetidos à ICP primária. 
Métodos: Estudo de coorte prospectivo extraído do banco de dados do Instituto de Cardiologia do Rio 
Grande do Sul, contendo 1.854 pacientes submetidos à ICP primária.
Resultados: Pacientes com CRM prévia (3,8%) mostraram perfil clínico, em geral, mais grave. O tempo de 
início dos sintomas até a chegada ao hospital foi menor nesse grupo (2,50 horas [1,46 – 3,66] vs. 3,99 horas 
[1,99-6,50]; p < 0,001) e o tempo porta-balão foi semelhante (1,33 hora [0,85-2,07] vs. 1,16 hora [0,88-1,58]; 
p = 0,12). O acesso femoral foi mais usado no grupo com CRM prévia (91,5% vs. 62,5%; p < 0,001). O uso de 
tromboaspiração manual foi menor nesse grupo (16,9% vs. 31,1%; p = 0,007), mas não houve diferença no 
uso de inibidor da glicoproteína IIb/IIIa (28,2% vs. 32,4%; p = 0,28). O sucesso angiográfico foi menor no 
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grupo com CRM prévia (80,3% vs. 93,3%; p = 0,009). Aos 30 dias, pacientes com CRM prévia apresentaram 
taxas similares de eventos cardíacos adversos maiores (14,1% vs. 11,2%; p = 0,28), e a mortalidade, embora 
numericamente mais alta, não foi estatisticamente significativa (13,2% vs. 7,0%; p = 0,07). 
Conclusões: Nessa análise contemporânea, pacientes com CRM prévia submetidos à ICP primária 
apresentaram perfil clínico mais grave e menor sucesso angiográfico, porém não mostraram diferenças 
nos desfechos clínicos em 30 dias.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The number of coronary artery bypass graft (CABG) surgeries pe-
aked in the 1990s and currently it remains a widely used alternative 
revascularization method in patients with coronary atherosclerosis.1 
It is also known that 50% of venous grafts become diseased, and 25% 
become occluded within a 5-year period postoperatively. Many of 
these patients seek emergency care with acute coronary syndrome.2 
Epidemiological data in Brazil are scarce, but the international lite-
rature reports that, it is a relatively frequent event. According to the 
National Cardiovascular Data Registry (NCDRTM), the percentage of 
patients with prior CABG who had acute myocardial infarction with 
ST-segment elevation (STEMI) was around 7.0% to 7.5% between 
2000 and 2010.3
The presence of prior CABG has been reported as an independent 
risk factor for adverse clinical outcomes in STEMI. In this scenario, 
diagnosis and treatment are always challenging. The clinical, elec-
trocardiographic, and laboratory findings are not always entirely 
elucidative,4 and when considering the existing anatomical issues 
and comorbidities, percutaneous coronary intervention (PCI) is so-
metimes more complex and has a worse prognosis.5 
Literature data show that in patients with STEMI and prior CABG 
submitted to primary balloon angioplasty, in-hospital mortality rates 
as well as those 6 months after the event were higher when compared 
to patients without prior CABG, especially when the culprit vessel was 
a saphenous vein graft.6 There are no recent data in the national litera-
ture evaluating this group of patients in this scenario.
This study aimed to evaluate the 30-day outcomes in a contempo-
rary cohort of patients with and without CABG, submitted to primary 
PCI in a tertiary referral hospital with a high volume of patients. 
Methods
Patients
This was a prospective cohort study that selected patients from 
an active database, which included all consecutive patients that pre-
sented with STEMI undergoing primary PCI at the Instituto de Car-
diologia do Rio Grande do Sul, Fundação Universitária de Cardiologia, 
in Porto Alegre (RS), Brazil. The assessed data and patients were tho-
se recorded from January 2010 to December 2013. The project was 
approved by the local Ethics Committee. All patients were informed 
about the study and signed an Informed Consent.
The inclusion criteria were the presence of STEMI treated within 
the first 12 hours. STEMI was defined as typical chest pain at rest 
associated with ST-segment elevation of at least 1 mm in two conti-
guous leads in the frontal plane or 2 mm in the horizontal plane, or 
typical chest pain at rest in patients with new, or presumably new 
left bundle branch block in the 12-lead electrocardiogram. Exclusion 
criteria were time of symptom onset until arrival at the hospital lon-
ger than 12 hours, age younger than 18 years, or unwillingness to 
participate in the study.
Primary percutaneous coronary intervention
The decision to contact the Hemodynamics Service was made 
by the assistant team responsible for patient care in the emer-
gency room, upon patient arrival. In accordance with the insti-
tut ional routines, the init ial adjunct ant iplatelet therapy 
included a loading dose of 300 mg of acetylsalicylic acid and a 
P2Y12 inhibitor (300 to 600 mg of clopidogrel, 180 mg of ticagre-
lor, or 60 mg of prasugrel). The use of additional anticoagulant 
therapy (heparin 70 to 100 IU/kg) while still in the emergency 
room was performed at the discretion of the team responsible 
for initial care. For patients who had not received heparin in the 
emergency room, the drug was prescribed in the interventional 
laboratory by the interventional cardiology team at the time of 
the procedure. These professionals were also responsible for de-
ciding whether or not use glycoprotein IIb/IIIa inhibitors, as well 
as other adjunctive medications.
Demonstration of the culprit vessel was performed in at least 
two views. The access route, PCI technique, the use of thrombus 
aspiration, and number of stents used were left to the operator’s 
discretion. Coronary f low before and after the procedure was 
evaluated according to the Thrombolysis in Myocardial Infarction 
(TIMI) criteria.7 
Data collection, outcomes and clinical follow-up
All patients were interviewed by the investigators at hospital ad-
mission. Angiographic, clinical, and laboratory data were collected 
using a standard questionnaire. Patients were visited daily during 
hospital stay by one of the researchers to evaluate the occurrence of 
in-hospital clinical outcomes. The occurrence of cardiovascular 
events 30 days after the procedure was assessed by telephone con-
tact and/or medical record review.
Major adverse cardiac events (MACE) were defined as the combi-
nation of mortality from all causes, myocardial infarction, or need 
for urgent revascularization. Myocardial infarction was characteri-
zed as the presence of recurrent chest pain associated with new ele-
vation of serum biomarkers (after the initial decline in the natural 
curve) associated with ST-segment elevation and/or new pathologi-
cal Q waves. Urgent revascularization was considered as the need to 
perform a new revascularization procedure, either percutaneous or 
surgical, due to recurrent ischemia. 
Additionally, stroke was defined as the development of sudden-
-onset focal neurological deficit, irreversible and/or causing death 
within 24 hours. Major bleeding was considered as the occurrence of 
clinically evident bleeding, a decrease in hemoglobin > 5 g/dL or in 
hematocrit > 15%, or development of hemorrhagic stroke. Stent 
thrombosis was classified as sudden occlusion of the treated vessel, 
confirmed by angiography during the in-hospital stay. 
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Statistical analysis 
The results were expressed as mean and standard deviation or 
absolute and relative frequencies, when appropriate. Variables 
with asymmetric distribution were expressed as median and in-
terquartile range. The chi-squared test or Fisher's exact test was 
used for categorical variables. For continuous variables, the 
analysis of variance (ANOVA) and Tukey’s test for multiple compa-
risons were used in the case of normal distribution, whereas the 
Kruskal-Wallis test was used for variables with asymmetric dis-
tribution. Statistical significance was defined as a two-tailed 
p-value < 0.05.
Data were collected in a Microsoft Access database (Microsoft 
Corporation – Redmond, USA) and statistical analysis was perfor-
med using the tools of the Statistical Package for Social Sciences 
(SPSS) for Windows, version 17.0 (IBM Corp.– Armonk, USA). 
Results
Of the 1,854 consecutive patients with STEMI and undergoing 
primary PCI, analyzed from 2010 to 2013, 71 (3.8%) had a history of 
prior CABG (Fig. 1). Table 1 describes the clinical, angiographic, and 
procedure characteristics. Patients with prior CABG were older, with 
Table 1
Clinical, angiographic, and procedure characteristics.





Age, years 65.6 ± 10.6 60.0 ± 11.7 < 0.001
Male gender, n (%) 56 (78.9) 1,240 (69.5) 0.09
Arterial hypertension, n (%) 60 (84.5) 1,134 (63.6) < 0.001
Dyslipidemia, n (%) 44 (62.0) 612 (34.2) < 0.001
Diabetes mellitus, n (%) 25 (35.2) 415 (23.8) 0.02
Family history of CAD, n (%) 28 (39.4) 544 (30.5) 0.09
Smoking, n (%) 13 (18.3) 773 (43.4) < 0.001
Prior myocardial infarction, n (%) 51 (71.8) 329 (18.5) < 0.001
Chronic renal failure, n (%) 2 (2.8) 45 (2.5) 0.70
Prior PCI, n (%) 35 (49.3) 266 (14.9) < 0.001
Congestive heart failure, n (%) 15 (21.1) 82 (4.6) < 0.001
Prior AMI, n (%) 18 (25.4) 794 (44.5) < 0.001
Killip IV, n (%) 2 (2.8) 104 (5.8) 0.21
Left bundle branch block, n (%) 2 (2.8) 19 (1.1) 0.17
Right ventricular infarction, n %) 7 (9.9) 211 (11.8) 0.63
cAVB, n (%) 1 (1.4) 50 (2.8) 0.41
Delta T, hours 2.50 [1.46- 3.66] 3.99 [1.99-6.50] < 0.001
Door-to-balloon time, hours 1.33 [0.85-2.07] 1.16 [0.88-1.58] 0.12
TIMI score 3.7 ± 2.1 3.0 ± 2.1 0.01
TIMI 3 flow, pre, n (%) 25 (35.2) 367 (20.6) 0.004
TIMI 3 flow, post, n (%) 61 (85.9) 1634 (91.6) 0.08
CK-MB peak, mg/dL 29.5 [14.0-61.0] 43.0 [18.0-84.5] 0.06
Troponin T peak, pg/mL 1,446 [335-4,598] 2,704 [764-6,131] 0.03
Intra-aortic balloon, n (%) 2 (2.8) 45 (2.5) 0.55
Pacemaker use, n (%) 1 (1.4) 82 (5.0) 0.20
Thrombus aspiration, n (%) 12 (16.9) 555 (31.1) 0.007
GP IIb/IIIa inhibitors, n (%) 20 (28.2) 578 (32.4) 0.28
Femoral access, n (%) 65 (91.5) 1,114 (62.5) < 0.001
CABG: coronary artery bypass surgery; CAD: coronary artery disease; PCI: percutaneous coronary intervention; AMI: acute myocardial infarction; cAVB: complete atrioventricular block; TIMI: Thrombolysis in Myo-
cardial Infarction; CK-MB: creatine kinase-myocardial band; GP IIb/IIIa: glycoprotein IIb/IIIa inhibitors.
Figure 1. Study flowchart. STEMI: ST-segment elevation myocardial infarction; CABG: coronary artery bypass graft surgery.
1,854 consecutive patients 
with STEMI




n = 30 
(42,3%) 
Native culprit
n = 39 
(54,9%)
No culprit
n = 2 
(2,8%)
71 patients with 
prior CABG 
(3.8%)
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higher prevalence of diabetes mellitus, dyslipidemia, arterial hyper-
tension, prior acute myocardial infarction, and PCI, but there were 
fewer smokers and anterior wall infarctions. There were no signifi-
cant differences regarding the incidence of cardiogenic shock (Killip 
IV), right ventricular infarction, or presence of left bundle branch 
block in the electrocardiogram between the groups. 
The time from symptom onset to arrival at the hospital (delta T) 
was significantly lower in the group with prior CABG (2.50 hours 
[1.46 to 3.66] vs. 3.99 hours [from 1.99 to 6.50]; p < 0.001). The door-
-to-balloon time was similar in both groups (1.33 hour [0.85 to 2.07] 
vs. 1.16 hour [0.88 to 1.58]; p = 0.12). Patients with prior CABG had 
higher incidence of TIMI 3 flow before the procedure, but there was 
a tendency to lower TIMI 3 flow after the procedure (85.9% vs. 91.6%; 
p = 0.08). Patients with prior CABG had lower serum troponin levels 
than those without prior CABG, as well as a trend to a lower level of 
creatine kinase-myocardial band (CK-MB).
Femoral access was most often used in this group (91.5% vs. 
62.5%; p < 0.001). The use of manual thrombus aspiration was signi-
ficantly lower in the group with prior CABG (16.9% vs. 31.1%; 
p = 0.007); however, no difference in glycoprotein inhibitor use IIb/
IIIa was observed between the two groups. Angiographic success 
was lower in the group with prior CABG (80.3% vs. 93.3%; p = 0.009).
Patients with prior CABG had similar rates of MACE (14.1% vs. 
11.2%; p = 0.28) and mortality, which, although numerically higher, 
was not statistically significant (13.2% vs. 7 0%; p = 0.07) when com-
pared to patients without prior CABG (Table 2).
As shown in Tables 3 and 4, prior CABG patients were stratified ac-
cording to the type of treated vessel. The latter was identified as a sa-
phenous vein graft in 30 patients (42.3%), and as the native vessel in 39 
patients (54.9%); the culprit vessel could not be defined in 2 patients.
Patients from the two groups, in general, did not show any diffe-
rences in relation to clinical characteristics. Pre- (16.7% vs. 48.7%; 
p = 0.005) and post-procedure TIMI 3 flows (78.0% vs. 92.3%; p = 0.07) 
were lower in the venous graft group. The use of thrombus aspira-
tion (10.2% vs. 23.1%; p = 0.02) was lower, but the use of glycoprotein 
IIb/IIIa inhibitors was higher (50.0% vs. 10.3%; p < 0.001) in this 
group. Angiographic success was similar (80.2% vs. 82.1%; p = 0.37), 
as well as 30-day MACE (13.3% vs. 17.9%; p = 0.15).
Discussion
This study shows a contemporary and representative sample of 
patients with STEMI and prior CABG. The rate of 3.8% of patients 
Table 2
30-day clinical outcomes.





MACE, n (%) 10 (14.1) 199 (11.2) 0.28
Death, n (%) 9 (13.2) 124 (7.0) 0.07
Acute  myocardial infarction, n (%) 1 (1.5) 73 (4.1) 0.25
Urgent CABG, n (%) 1 (1.5) 11 (0.6) 0.38
Stroke, n (%) 2 (2.9) 15 (0.8) 0.09
Major bleeding, n (%) 2 (2.9) 36 (2.0) 0.65
Stent thrombosis, n (%) 0 44 (2.5) 0.17
CABG: coronary artery bypass graft surgery; MACE: major adverse cardiovascular events. 
Table 3
Clinical characteristics among patients with prior  coronary artery bypass surgery, according to the type of vessel treated.
Characteristics Saphenous vein graft  
(n = 71)
Native vessel  
(n = 39)
p-value
Age, years 66.7 ± 10.4 64.7 8 ± 10.7 0.44
Male gender, n (%) 22 (73.3) 34 (87.2) 0.15
Arterial hypertension, n (%) 27 (90.0) 32 (82.1) 0.32
Dyslipidemia, n (%) 22 (74.6) 22 (56.4) 0.10
Diabetes mellitus, n (%) 8 (27.1) 16 (41.0) 0.21
Family history of CAD, n (%) 14 (47.5) 13 (33.3) 0.21
Smoking, n (%) 8 (27.1) 5 (12.8) 0.35
Prior myocardial infarction, n (%) 3 (10.2) 16 (41.0) 0.004
Chronic renal failure, n (%) 3 (10.2) 7 (17.9) 0.43
Prior PCI, n (%) 16 (54.2) 20 (51.3) 0.53
Congestive heart failure, n (%) 23 (78.0) 31 (79.5) 0.50
Prior AMI, n (%) 8 (27.1) 16 (41.0) 0.47
Killip IV, n (%) 1 (3.4) 1 (2.6) > 0.99
Left bundle branch block, n (%) 1 (3%) 1 (2.6) 0.68
Right ventricular infarction, n (%) 2 (7%) 5 (12.8) 0.36
cAVB, n (%) 0 1 (2.6) 0.57
Delta T, hour 2.00 (1.14-5.26) 2.73 (5.1-9.99) 0.78
Door-to-balloon time, hour 1.16 (0.88-1.58) 1.35 (0.97-2.04) 0.53
TIMI score 3.9 ± 2.1 3.5 ± 2.1 0.50
TIMI 3 flow, pre, n (%) 5 (16.7) 19 (48.7) 0.005
TIMI 3 flow, post, n (%) 23 (78.0) 36 (92.3) 0.07
CK-MB peak, mg/dL 18.00 (11.00-33.00) 39.00 (14.75-75.00) 0.40
Troponin T peak, pg/mL 802.00 (263.00-2,374.00) 377.50 (76.78-2,789.00) 0.03
Intra-aortic balloon pump, n(%) 1 (3.4) 1 (2.6) 0.57
Pacemaker use, n (%) 0 1 (2.6) 0.57
Thrombus aspiration, n (%) 3 (10.2) 9 (23.1) 0.02
GP IIb/IIIa inhibitors, n (%) 15 (50.0) 4 (10.3) < 0.001
Femoral access, n (%) 18 (61.0) 36 (92.3) 0.17
CAD: coronary artery disease; PCI: percutaneous coronary intervention; AMI: acute myocardial infarction; cAVB: complete atrioventricular block; TIMI: Thrombolysis in Myocardial Infarction; CK-MB: creatine kina-
se-myocardial band; GP IIb/IIIa: glycoprotein IIb/IIIa inhibitors.
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with prior CABG found in this analysis is compatible with most re-
ports in the literature (2.5% to 5.3%) and slightly lower than that 
reported in some more recent studies, in which the prior CABG rate 
was around 7%.8
The trend towards higher 30-day mortality in the group with 
prior CABG, although it may have been influenced by the sample 
size, suggests that these patients do not necessarily have a worse 
prognosis in the first 30 days after the index event. Similarly, there is 
no difference in MACE or mortality rate between patients with sa-
phenous venous graft culprit lesion in relation to native vessel cul-
prit lesion in those patients with prior CABG.
Preliminary analyses suggest increased mortality in patients 
with STEMI and prior CABG, especially in patients whose culprit ves-
sel was a venous graft. A study carried out in the early 2000s showed 
significantly lower success rate of balloon-PCI and TIMI 3 flow after 
the procedure in 58 patients with prior CABG.6 Hospital mortality 
was higher among patients with prior CABG and in those with a ve-
nous graft as the culprit vessel. This difference between the analyses 
must be related to a combination of inadequate adjunct therapy, as 
there was no standard dual antiplatelet therapy at that time, in addi-
tion to non-routine use of stents and low success rates of reperfusion 
using primary PCI.
Nikolski et al.,9 in a sub-analysis of the HORIZONS-AMI study, 
showed that patients with prior CABG, when compared with pa-
tients with no history of surgery, had higher MACE rates at the end 
of 3 years, due to significant differences in reinfarction, stroke, and 
even mortality rates. Additionally, patients with prior CABG were 
associated with greater delay to mechanical reperfusion, as well as 
lower primary PCI rates and patency of the culprit vessel.
In another analysis, Brodie et al.10 also showed worse outcomes at 
1 year and 5 years in patients with prior CABG who had the venous 
graft as culprit vessel. The mortality rate of this group was approxi-
mately three-fold higher when compared to those with a culprit na-
tive vessel, with statistical significance. However, this study 
included patients from the 1980s to the early 2000s; its main limita-
tion is the use of stents in only 33% of cases, distal protection devices 
in very few patients and, above all, the absence of dual antiplatelet 
therapy protocol – a fact that is quite different from the current rea-
lity demonstrated in the present study, in which the optimal use of 
antiplatelet therapy and stent implant was the rule.
In a very recent study, Kohl et al.11 demonstrated that there was 
no difference in mortality between the groups with and without 
prior CABG in 30 days and 1 year, respectively. In the 5-year analysis, 
a significant increase in mortality was observed in patients with 
prior CABG. As observed in the present study, that study showed no 
differences in mortality when groups were stratified according to 
the culprit vessel, being either the native vessel or venous graft.
Study limitations
This was an observational study and, therefore, definitive conclu-
sions about the effect of certain therapies on the outcomes may have 
been affected by confounding bias. The number of patients included 
in the study, although fairly representative, may not have been 
enough to demonstrate differences between the two groups regar-
ding outcomes. Additionally, these results cannot be generalized in 
relation to those of other centers with lower patient volumes. Angio-
graphic analysis was not independently assessed by a different an-
giographic laboratory, a limitation that is also shared by other 
registries of patients with primary PCI. Similarly, the long-term 
follow-up of these patients was not carried out, which may or may 
not confirm the short-term findings. 
Conclusions 
In this contemporary cohort of patients with prior  coronary ar-
tery bypass graft  surgery undergoing primary percutaneous coro-
nary intervention  for the treatment of acute myocardial infarction 
with ST segment elevation , it was observed that although patients 
with prior  coronary artery bypass graft  surgery had less angiogra-
phic success, there was no significant difference in overall mortality 
or in  major adverse cardiac event rates in the short term, when com-
pared to those without prior revascularization. When the group 
with prior  coronary artery bypass graft  surgery was stratified ac-
cording to the culprit vessel, there was also no difference regarding 
the outcome between the types of treated vessels. These findings 
demonstrate the importance for a tertiary center to use well-de-
fined protocols in the contemporary treatment of  acute myocardial 
infarction with ST segment elevation, thus causing the outcomes of 
patients with prior  coronary artery bypass graft  surgery to be simi-
lar to those of an unselected patient population. Further studies 
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Table 4
30-day clinical outcomes among patients with prior  coronary artery bypass graft surgery, according to the type of vessel treated.
Outcomes Saphenous vein graft  
(n = 71)
Native vessel  
(n = 39)
p-value
MACE, n (%) 4 (13.3) 7 (17.9) 0.15
Death, n (%) 2 (6.6) 4 (10.3) 0.23
Acute myocardial infarction, n (%) 0 1 (2.6) 0.57
Urgent coronary artery bypass graft, n (%) 1 (3.3) 0 0.44
Stroke, n (%) 1 (3.3) 1 (2.6) 0.85
Major bleeding, n (%) 1 (3.3) 0 0.25
Stent thrombosis, n (%) 0 0 NA
MACE: major adverse cardiovascular events; NA: not applicable.
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